BRD5529 manufacturers
- BRD5529
-
- $52.00 / 2mg
-
2026-04-22
- CAS:1358488-78-4
- Min. Order:
- Purity:
- Supply Ability: 10g
- BRD5529
-
- $52.00 / 2mg
-
2025-08-22
- CAS:1358488-78-4
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | BRD5529 Basic information |
| Product Name: | BRD5529 | | Synonyms: | BRD5529;BRD5529
(BRD-5529;BRD5529 >=98% (HPLC);3-Pyridinecarboxylic acid, 2-[4'-(aminocarbonyl)[1,4'-bipiperidin]-1'-yl]-5-[(4-methylbenzoyl)amino]- | | CAS: | 1358488-78-4 | | MF: | C25H31N5O4 | | MW: | 465.54 | | EINECS: | | | Product Categories: | | | Mol File: | 1358488-78-4.mol |  |
| | BRD5529 Chemical Properties |
| Boiling point | 671.6±55.0 °C(Predicted) | | density | 1.327±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: 2mg/mL, clear (warmed) | | pka | 1.87±0.36(Predicted) | | form | Solid | | color | Light yellow to yellow | | InChIKey | ZXWHESBABUHJBE-UHFFFAOYSA-N | | SMILES | CC1=CC=C(C(NC2=CC(C(O)=O)=C(N3CCC(N4CCCCC4)(C(N)=O)CC3)N=C2)=O)C=C1 |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | BRD5529 Usage And Synthesis |
| Description | BRD5529 is a selective inhibitor of CARD9, disrupting TRIM62 recruitment. BRD5529 inhibits TRIM62-mediated ubiquitinylation of CARD9, and demonstrates cellular activity and selectivity in CARD9-dependent pathways. | | Uses | BRD5529 is an effective dose-dependent CARD9-TRIM62 protein–protein interaction (PPI) inhibitor with an IC50 value of 8.6 μM. BRD5529 has potency and complete inhibition of CARD9 ubiquitinylation in vitro, also has favorable solubility. BRD5529 can be used for the research of inflammatory bowel disease (IBD) such as Crohn’s disease (CD) and ulcerative colitis (UC)[1][2]. | | in vivo | BRD5529 (i.p.; 0.1 or 1.0 mg/kg; daily, for 2 weeks) displays no inherent safety concerns in initial general safety and toxicology assessments[2]. | Animal Model: | Pneumocystis pneumonia (PCP) model[2] | | Dosage: | 0.1 or 1.0 mg/kg | | Administration: | intraperitoneally (IP), daily, for 2 weeks | | Result: | Resulted no significant changes in daily or final weight gain and proinflammatory cytokines showed no major differences.
Showed no significant change of lung, liver, and kidney in pathology scoring.
|
| | References | [1] Leshchiner ES, et al. Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatorybowel disease. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):11392-11397. DOI:10.1073/pnas.1705748114
[2] Theodore J Kottom, et al. Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9. Drugs R D. 2022 Jun;22(2):165-173. DOI:10.1007/s40268-022-00389-0 |
| | BRD5529 Preparation Products And Raw materials |
|